Breckenridge Pharmaceutical Inc, the US subsidiary of Spanish pharmaceutical company Towa International, announced on Wednesday that it has received final approval from the US Food and Drug Administration (FDA) for Everolimus Tablets for Oral Suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis (SWX:NOVN).
The company's partner Natco Pharma Limited, India holds the ANDA and Breckenridge plans to launch the product immediately.
Everolimus TFOS, a kinase inhibitor, is indicated for the treatment of adult and paediatric patients aged one year and older with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review
FDA grants Regenerative Medicine Advanced Therapy designation to Beacon Therapeutics' laru-zova
AstraZeneca and Daiichi Sankyo's Enhertu approved in US for earlier treatment of breast cancer
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
ColdVentures partners with Medco Sports Medicine to combat heat stroke
eNeura Inc expands access to innovative migraine treatment
Norgine and X4 advance mavorixafor approval in Europe
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Biogen submits applications for higher dose regimen of nusinersen in SMA